Skip to main content

Table 5 Mean percent blood glucose reduction in diabetic rats (N = 6)

From: Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models

Time

(h)

Gliclazide

Nevirapine

Nevirapine + Gliclazide*(Single dose treatment)

Nevirapine + Gliclazide*(Multiple dose treatment)

1

33.45 ± 1.76

02.08 ± 0.38

32.42 ± 1.47

33.23 ± 1.63

2

42.50 ± 1.40

04.34 ± 1.40

41.68 ± 1.27

42.28 ± 1.32

3

31.87 ± 1.68

04.42 ± 1.62

30.69 ± 1.61

31.66 ± 1.66

4

25.88 ± 1.42

06.11 ± 1.61

25.43 ± 1.47

25.82 ± 1.34

6

36.89 ± 1.30

06.28 ± 1.53

36.25 ± 1.48

36.78 ± 1.38

8

44.46 ± 1.46

03.08 ± 0.54

43.25 ± 1.35

44.37 ± 1.33

10

28.72 ± 1.76

01.67 ± 0.67

27.93 ± 1.55

28.92 ± 1.68

12

24.39 ± 1.81

01.64 ± 0.71

23.81 ± 1.80

24.98 ± 1.83

  1. *Statistically no significance compared to gliclazide control